Alkem forms alliance with Haw Par to market Tiger Balm products in India
Through this, two companies aims to tap OTC analgesic market in India, estimated at Rs 2,000 crore07-02-2017
07-02-2017
Alkem enters into an alliance with Haw Par to exclusively market, sell and distribute Tiger Balm range of products in India
Alkem Laboratories Ltd has informed BSE regarding a Press Release dated February 07, 2017 titled "Alkem enters into an alliance with Haw Par to exclusively market, sell and distribute Tiger Balm range of products in India".07-02-2017
Intimation of Conference Call on Q3FY17 Results
Alkem Laboratories Ltd has informed BSE regarding "Intimation of Conference Call on Q3FY17 Results".25-01-2017
Board Meeting Intimation for Results
Alkem Laboratories Ltd has informed BSE that a meeting of the Board of Directors of the Company is scheduled to be held on February 10, 2017, inter alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2016.25-01-2017
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Alkem Laboratories Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.11-01-2017
Shareholding for the Period Ended December 31, 2016
Alkem Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here06-01-2017
Closure of Trading Window
Alkem Laboratories Ltd has informed BSE that in terms of Companys Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, the trading window will remain closed from December 30, 2016 until the expiry of 48 hours after the date on which the Financial Results of the Company for the quarter and nine months ended December 31, 2016 are communicated to the Stock Exchanges.29-12-2016
Alkem Labs gets EIR from USFDA for Daman plant
Drug firm Alkem Laboratories has received establishment inspection report (EIR) for its Daman facility after it had submitted detailed remedial plan to the US health regulator. United States...23-12-2016
Alkem receives EIR from the US FDA for its Daman formulation facility
Alkem Laboratories Ltd has informed BSE regarding a Press Release dated December 23, 2016 titled "Alkem receives EIR from the US FDA for its Daman formulation facility".23-12-2016
Alkem's Ankleshwar APIs facility receives three 483 observations from US FDA
These observations were issued following an inspection conducted by US FDA at the site from December 5-9, 201613-12-2016